Association of major histocompatibility complex determinants with the development of symptomatic and asymptomatic genital herpes simplex virus type 2 infections

Journal of Infectious Diseases

Volumn 179, Issue 5, 1999, Pages 1077-1085

  Lekstrom Himes, Julie A ^a,b,c   Hohman, Patricia ^a,b,c   Warren, Terri ^a,b,c   Wald, Anna ^a,b,c   Nam, Jun Mo ^a,b,c   Simonis, Toni ^a,b,c   Corey, Lawrence ^a,b,c   Straus, Stephen E ^a,b,c  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b Westover Heights Clinic   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA B27 ANTIGEN; HLA C ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ADULT; ARTICLE; FEMALE; GENE FREQUENCY; GENITAL HERPES; HERPES SIMPLEX VIRUS 2; HUMAN; IMMUNOBLOTTING; INFECTION RISK; MAJOR CLINICAL STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; PRIORITY JOURNAL; RECURRENT INFECTION; SYMPTOMATOLOGY;

ADULT; ALLELES; ANTIBODIES, VIRAL; BLOTTING, WESTERN; COHORT STUDIES; FEMALE; GENE FREQUENCY; GENES, MHC CLASS I; GENES, MHC CLASS II; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HLA ANTIGENS; HLA-B27 ANTIGEN; HLA-C ANTIGENS; HUMANS; MALE; PROSPECTIVE STUDIES;

EID: 0033043303     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314729     Document Type: Article

References (67)

1. 1. Stanberry LR, ed. Genital and neonatal herpes. New York: John Wiley & Sons, 1996.
2. 2. Corey L. Spear PG. Infections with herpes simplex viruses. N Engl J Med 1986;314:686 91;749-57.
3. 3. Koutsky LA, Stevens CE, Holmes KK, et al. Underdiagnosis of genital herpes by current clinical and viral-isolation procedures. N Engl J Med 1992; 326:1533-9.
4. 4. Mertz GJ, Schmidt O, Jourden JL, et al. Frequency of acquisition of first episode genital infection with herpes simplex virus from symptomatic and asymptomatic source contacts. Sex Transm Dis 1985;12:33-9.
5. 5. Wald A, Zeh J, Barnum G, Davis LG, Corey L. Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir. Ann Intern Med 1996;124:8-15.
6. 6. Wald A, Zeh J, Selke S, Ashley RL, Corey L. Virologic characteristics of subclinical and symptomatic genital herpes infections. N Engl J Med 1995;333:770-5.
7. 7. Rooney JJ, Felser JM, Ostrove JM, Straus SE. Acquisition of genital herpes from an asymptomatic sexual partner. N Engl J Med 1986;314:1561-4.
8. 8. Brown ZA, Benedetti J, Ashley R, et al. Neonatal herpes simplex virus infection in relation to asymptomatic maternal infection at the time of labor. N Engl J Med 1991;324:1247-52.
9. 9. Mertz. GJ, Benedetti J, Ashley R, Selke S, Corey L. Risk factors for sexual transmission of genital herpes. Ann Intern Med 1992;116:197-202.
10. 10. Ashley RL, Militoni J, Lee F, et al. Comparison of Western blot (immunoblot) and G-specific immunodot enzyme assay for detecting antibodies to herpes simplex virus types 1 and 2 in human sera. J Clin Microbiol 1988;26: 662-7.
11. 11. Rammensee HG, Bachmann J, Stevanovic S, eds. MHC ligands and peptide motifs. Molecular biology intelligence unit, Landes Bioscience. Austin, TX: Chapman & Hall, 1997.
12. 12. Erlich HA, McDevitt HO, Lock CB. The role of the MHC in autoimmune disease. In: Bona CA, Siminovitch KA, Zanetti M, Theofilopoulos AN, eds. The molecular pathology of autoimmune diseases. Chur, Switzerland: Harwood Academic Publishers, 1993;101-11.
13. 13. Tiwari JL, Terasaki PI. HLA and disease associations. New York: Springer-Verlag. 1985.
14. 14. Lopez-Larrea C, Gonzalez-Roces S, Alverez V. HLA-B27 structure, function and disease association. Curr Opin Rheumatol 1996;8:296-308.
15. 15. Strettell MD, Thomson LJ, Donaldson PT, Bunce M, O'Neill CM, Williams R. HLA-C genes and susceptibility to type 1 autoimmune hepatitis. Hepatology 1997;26:1023-6.
16. 16. Steel CM, Ludlam CA, Beatson D, et al. HLA haplotype A1 B8 DR3 as a risk factor for HIV-related diseases. Lancet 1988;1:1185-8.
17. 17. Gallina G, Cumbo V, Messina P, Caprera V, Lio D, Caruso C. Lack of correlation between HLA-B35 resistance against herpes labialis and antibody titers to HSV-1. Oral Surg Oral Med Oral Pathol 1989;68:167-70.
18. 18. Lio D, Caccamo N, d'Anna C, Cigna D, Candore G, Caruso C. Viral antibody titers are influenced by HLA-CD2 phenotype. Exp Clin Immunogenet 1994;11:182-6.
19. 19. Jabbar AA, al-Samaria SA, al-Amar NS. HLA antigens associated with susceptibility to herpes simplex virus infection. Dis Markers 1991;9:281-7.
20. 20. Blackwelder WC, Dolin R, Mittal KK, McNamara PM, Payne FJ. A population study of herpesvirus infections and HLA antigens. Am J Epidemiol 1982;115:569-76.
21. 21. Terasaki PI. Histocompatibility testing. In: Danovitch GM, ed. Handbook of kidney transplantation. Boston: Little, Brown, 1991;43-66.
22. 22. Vartdal F, Gaudernack G. Funderud S. HLA class I and II typing using cells positively selected from blood by immunomagnetic isolation, a fast and reliable technique. Tissue Antigens 1986;28:301-12.
23. 23. Park MS, Tonai RJ. Phenotypic frequencies of the class II (DR, DQ) DNA alleles by the patterns of sequence-specific primer mixtures (SSPM) in four different populations and the probable haplotypes between DRB1 allele and DQB1 allele. In: Terasaki PI, ed. Clinical transplants, 1992. Los Angeles: UCLA Tissue Typing Laboratory, 1993;475-500.
24. 24. Tonai RT, Terasaki PI. DNA typing of HLA-DR by sequence-specific primers. In: Nikaein A, ed. ASHI manual, 3d ed. 1994;IV.C.4.1.
25. 25. Nam J, Gart JJ. Berstein's and gene-counting methods in generalized ABO-like systems. Ann Hum Genet 1976;39:361-73.
26. 26. Gart JJ, Nam J. Statistical methods for genetic studies of HLA and cancer. In: Cornell RG, ed. Statistical methods in cancer studies. New York: Dekker, 1984;229-66.
27. 27. Armitage P. Statistical methods in medical research. New York: John Wiley & Sons, 1971;131-8.
28. 28. Miller RG Jr. Simultaneous statistical inference. New York: McGraw-Hill, 1966.
29. 29. Yasukawa M, Zarling JM. Human cytotoxic T cell clones directed against herpes simplex virus-infected cells. I. Lysis restricted by HLA class II MB and DR antigens. J Immunol 1984;133:422-7.
30. 30. Koelle DM, Posavad CM, Barnum GR, Johnson ML, Frank JM, Corey L. Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes. J Clin Invest 1998;101: 1500-8.
31. 31. Posavad CM, Koelle DM, Corey L. Tipping the scales of herpes simplex virus reactivation: the important responses are local. Nat Med 1998;4: 381-2.
32. 32. Levitskaya J, Coram M, Levitsy V, et al. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 1995;375:685-8.
33. 33. Wiertz E, Hill A, Tortorello D, Ploegh H. Cytomegaloviruses use multiple mechanisms to elude the host immune response. Immunol Lett 1997;57: 213-6.
34. 34. Farrell HE, Vally H. Lynch DM. et al. Inhibition of natural killer cells by a cytomegalovirus MCH class I homologue in vivo. Nature 1997;386: 510-4.
35. 35. Hill A, Jugovic P, York I, et al. Herpes simplex virus turns off the TAP to evade host immunity. Nature 1995;375:411-5.
36. + CTL clones recognize HSV-2 infected fibroblasts after treatment with IFN-γ or when virion host shutoff functions are disabled. J Immunol 1996;156:3901-10.
37. 37. Schust DJ, Hill AB, Ploegh HL. Herpes simplex virus blocks intracellular transport of HLA-G in placentally derived human cells. J Immunol 1996;157:3375-80.
38. 38. 'Pazmany L, Mandelboim O, Vales-Gomez M, Davis DM, Reyburn HT, Strominger JL. Protection from natural killer cell -mediated lysis by HLA-G expression on target cells. Science 1996;274:792-4.
39. 39. Wagner EK, Bloom DC. Experimental investigation of herpes simplex virus latency. Clin Microbiol Rev 1997;10:419-43.
40. + cytotoxic T lymphocyte responses. Proc Natl Acad Sci USA 1997;94:10289-94.
41. 41. Chan WL, Tizard ML, Faulkner L. Proliferative T-cell response to glycoprotein B of the human herpesviruses: the influence of MHC and sequence of infection on the pattern of cross-reactivity. Immunology 1989;68: 96-101.
42. 42. Curtsinger JM, Liu YN, Radeke R, Bryon MK, Fuad S, Bach FH, Gehrz RC. Molecular analysis of the immune response to human cytomegalovirus glycoprotein B (gB). II. Low gB-specific T and B cell responses are associated with expression of certain HLA-DR alleles. J Gen Virol 1994;75:301-7.
43. 43. Murray RJ, Kurilla MG, Brooks JM, Thomas WA, Rowe M, Kieff E, Rickinson AB. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J Exp Med 1992;176:157-66.
44. 44. Schofield JK, Tatnall FM, Brown J, McCloskey D, Navarette C, Leigh IM. Recurrent erythema multiforme: tissue typing in a large series of patients. Br J Dermatol 1994;131:532-5.
45. 45. Khalil I, Lepage V, Douay C, et al. HLA DQB1*0301 allele is involved in the susceptibility to erythema multiforme. J Invest Dermatol 1991;97: 697-700.
46. 46. Simon M, Fuchs C. HLA pattern in patients with post-herpetic erythema exsudativum multiforme. Z Hautkr 1990;65:303-4.
47. 47. Kampgen E, Burg G, Wank R. Association of herpes simplex virus induced erythema multiforme with the human leukocyte antigen DQw3. Arch Dermatol 1988;124:1372-5.
48. 48. Koelle DM, Posavad CM, Barnum GR, Johnson ML, Frank JM, Corey L. Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes. J Clin Invest 1998;101: 1500-8.
49. 49. Jerome KR, Tait JF, Koelle DM, Corey L. Herpes simplex virus type 1 renders infected cells resistant to cytotoxic T-lymphocyte-induced apoptosis. J Virol 1998;72:436-41.
50. + cytotoxic T lymphocytes responses. Proc Natl Acad Sci USA 1997;94:10289-94.
51. 51. Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele ofthe CCR5 structural gene. Science 1996;273:1856-62.
52. 52. Pottern LM, Gart JJ, Nam J, et al. HLA and multiple myeloma among black and white men: evidence of a genetic association. Cancer Epidemiol Biomarkers Prev 1992;1:177-82.
53. 2m. J Clin Invest 1996;98:2746-55.
54. 54. Warner TF, Madsen J, Starling J, Wagner RD, Taurog JD, Balish E. Human HLA-B27 gene enhances susceptibility of rats to oral infection by Listeria monocytogenes. Am J Pathol 1996;149:1737-43.
55. 55. Laitio P, Virtala M, Salmi M, Pelliniemi LJ, Yu DT, Granfors K. HLA-B27 modulates intracellular survival of Salmonella enteritidis in human monocytic cells. Eur J Immunol 1997;27:1331-8.
56. 56. Caruso C, Candore G, Modica MA, et al. Major histocompatibility complex regulation of cytokine production. J Interferon Cytokine Res 1996;16: 983-8.
57. 57. McNeil AJ, Yap PL. Gore SM, et al. Association of HLA types A1-B8-DR3 and B27 with rapid and slow progression of HIV disease. QJM 1996;89: 177-85.
58. 58. Lenzi M, Frisoni M, Mantovani V, et al. Haplotype HLA-B8-DR3 confers susceptibility to hepatitis C virus-related mixed cryoglobulinemia. Blood 1998;91:2062-6.
59. 59. Wald A, Corey L, Cone R, Hobson A, Davis G, Zeh J. Frequent genital herpes simplex virus 2 shedding in immunocompetent women. Effect of acyclovir treatment. J Clin Invest 1997;99:1092-7.
60. 60. Biron CA, Byron KS, Sullivan JL. Severe herpesvirus infections in an adolescent without natural killer cells. N Engl J Med 1989;320:1731-5.
61. 61. Biassoni R, Falco M, Cambiaggi A, et al. Amino acid substitutions can influence the natural killer (NK) mediated recognition of HLA-C molecules. Role of serine-77 and lysine-80 in the target cell protection from lysis mediated by "Group2" or "Group1" NK clones. J Exp Med 1995; 182:605-9.
62. 62. Zappacosta F, Borrego F, Brooks AG, Parker KC, Coligan JE. Peptides isolated from HLA-Cw*0304 confer different degrees of protection from natural killer cell mediated lysis. Proc Natl Acad Sci USA 1997;94: 6313-8.
63. 63. Rajagopalan S, Long EO. The direct binding of a p58 killer cell inhibitory receptor to human histocompatibility leukocyte antigen (HLA) Cw4 exhibits peptide selectivity. J Exp Med 1997;185:1523-8.
64. 64. Mandelboim O, Wilson SB, Vales-Gomez M, Reyburn HT, Strominger JL. Self and viral peptides can initiate lysis by autologous natural killer cells. Proc Natl Acad Sci USA 1997;94:4604-9.
65. 65. Merriman TR, Todd JA. Genetics of autoimmune disease. Curr Opin Immunol 1995;7:786-92.
66. 66. Hill AVS. HIV and HLA: confusion or complexity. Nat Med 1996;2:395-6.
67. 67. Davenport M, Hill AVS. Reverse immunogenetics: from HLA-disease associations to vaccine candidates. Mol Med Today 1996;2:38-45.